What is the recommended treatment for hiccups, including non‑pharmacologic measures and pharmacologic options for persistent or intractable cases?

Treatment of Hiccups

For persistent or intractable hiccups, initiate treatment with baclofen or gabapentin as first-line pharmacologic therapy, with chlorpromazine or metoclopramide held in reserve, while simultaneously addressing any identifiable underlying cause.

Initial Approach

Begin by classifying hiccup duration to guide treatment intensity:

• Acute: <48 hours
• Persistent: >48 hours
• Intractable: >2 months

The most critical first step is identifying and treating the underlying cause when possible, as this provides the most effective management 1. Common etiologies include:

• Gastroesophageal reflux disease (most common gastrointestinal cause)
• Medication-induced (dexamethasone, chemotherapy agents, steroids)
• Central nervous system lesions
• Phrenic or vagus nerve irritation

Non-Pharmacologic Interventions

For acute hiccups, patient-directed behavioral-physical interventions are highly effective and should be attempted first. A recent 2025 randomized controlled trial demonstrated that teaching patients six behavioral-physical techniques significantly shortened median hiccup remission time from 3.0 hours to 0.17 hours 2. These interventions include:

• Breath-holding maneuvers
• Vagal stimulation techniques
• Respiratory pattern modifications

Acupuncture has demonstrated efficacy in cancer patients and should be considered as an adjunctive non-pharmacologic option 3.

Pharmacologic Treatment Algorithm

First-Line Agents

Baclofen is the most evidence-supported first-line agent, with data from randomized placebo-controlled trials 1, 4. It acts on the hiccup reflex arc and has a favorable side effect profile for long-term use.

• Dosing: Start low and titrate based on response
• Particularly effective for intractable cases 5

Gabapentin is an equally appropriate first-line choice, supported by prospective studies and favorable safety profile 1, 4.

• Can be used as monotherapy or added to baclofen for refractory cases 5
• Better tolerated than neuroleptic agents for chronic therapy

Second-Line Agents

Metoclopramide has randomized controlled trial evidence supporting its use 1, 4. Consider this when:

• Gastroparesis is suspected
• First-line agents fail or are contraindicated

Chlorpromazine is the only FDA-approved medication specifically for hiccups, but should be reserved for refractory cases due to its side effect profile 4, 1. A 2024 case report demonstrated successful resolution after baclofen failure 6.

Special Populations

Cancer patients receiving chemotherapy:

• Steroid rotation is most beneficial - replace dexamethasone with methylprednisolone or omit dexamethasone entirely 3
• This addresses medication-induced hiccups at their source
• Olanzapine has shown promise in this population 3

Palliative care patients: Consider the NCCN guidelines framework, which emphasizes symptom management and quality of life optimization 7.

Common Pitfalls and Caveats

⚠️ Critical warning: The same medications used to treat hiccups (particularly steroids and chemotherapy agents) can also induce them 5. Always review the medication list and consider drug-induced etiology.

⚠️ Avoid empiric chlorpromazine first: Despite FDA approval, chlorpromazine has a less favorable side effect profile compared to baclofen and gabapentin, particularly for long-term use 1.

⚠️ Don't overlook GERD: An empirical trial of anti-reflux therapy is appropriate given the high prevalence of gastrointestinal causes 1.

Refractory Cases

For truly intractable hiccups unresponsive to pharmacologic therapy:

• Consider dual or triple drug therapy combining agents with different mechanisms 6
• Phrenic nerve blocks may provide temporary relief
• Prescriptive positive pressure ventilation under anesthesia has shown success in case reports, utilizing neuromuscular blockade and vital capacity breaths to 25 cm H₂O 8
• Phrenic nerve stimulator placement is a last-resort surgical option

Evidence Quality Note

The evidence base for hiccup treatment remains limited. No adequately powered, well-designed trials exist 1. Treatment recommendations are based primarily on small randomized trials (baclofen, metoclopramide) and observational data (gabapentin, chlorpromazine). The 2025 systematic review confirms baclofen as the most consistently beneficial agent across studies 3.